Latest news with #LIfTBioSciences
Yahoo
04-06-2025
- Business
- Yahoo
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
LIfT BioSciences joins Bayer Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreement with Bayer HealthCare LLC, granting LIfT access to Bayer's state-of-the-art facilities in Cambridge, Massachusetts – one of the world's leading hubs for biotech innovation. This agreement provides LIfT with advanced infrastructure and shared services in a highly collaborative research environment, accelerating the development of its Immuno-Modulatory Alpha Neutrophil (IMAN) platform designed to overcome treatment resistance in solid tumours. 'We see a strong strategic fit with The Bayer Group who have supported using cell therapies to replace dysfunctional cell types in the body in other therapeutic settings, and have developed the world-class facilities and expertise to cost-effectivenely deliver those therapies that we can now look to benefit from. The Bayer offers a unique environment designed to support our kind of biotech innovation, and strengthen our transatlantic presence as we expand as a clinical stage company,' said Alex Blyth, Chief Executive Officer of LIfT Biosciences. Fiona Mack, Head Cambridge at Bayer HealthCare LLC said: 'The was created to provide cutting-edge biotech companies with the space, resources and network they need to accelerate their research and development. portfolio companies have been selected by a panel of experts within Bayer based upon the scientific merit and potential to substantially impact healthcare. LIfT, with its novel immunotherapy approach, exemplifies the type of company and innovative science that we aim to support and we believe they will be a great fit in our collaborative environment.' As part of the agreement, LIfT will gain access to a cutting-edge innovation space designed to support the unique needs of early-stage biotechs, with the flexibility to expand into larger 'pods' or private lab areas as operations grow. LIfT will also benefit from centralised procurement and operational support, enabling the team to focus on advancing its IMAN platform efficiently and safely. About LIfT BioSciencesLIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by reconstituting immune competence. LIfT's Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable total immune response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See Further informationInvestors:Alex Blyth ablyth@ Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@ in to access your portfolio
Yahoo
04-06-2025
- Business
- Yahoo
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
LIfT BioSciences joins Bayer Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreement with Bayer HealthCare LLC, granting LIfT access to Bayer's state-of-the-art facilities in Cambridge, Massachusetts – one of the world's leading hubs for biotech innovation. This agreement provides LIfT with advanced infrastructure and shared services in a highly collaborative research environment, accelerating the development of its Immuno-Modulatory Alpha Neutrophil (IMAN) platform designed to overcome treatment resistance in solid tumours. 'We see a strong strategic fit with The Bayer Group who have supported using cell therapies to replace dysfunctional cell types in the body in other therapeutic settings, and have developed the world-class facilities and expertise to cost-effectivenely deliver those therapies that we can now look to benefit from. The Bayer offers a unique environment designed to support our kind of biotech innovation, and strengthen our transatlantic presence as we expand as a clinical stage company,' said Alex Blyth, Chief Executive Officer of LIfT Biosciences. Fiona Mack, Head Cambridge at Bayer HealthCare LLC said: 'The was created to provide cutting-edge biotech companies with the space, resources and network they need to accelerate their research and development. portfolio companies have been selected by a panel of experts within Bayer based upon the scientific merit and potential to substantially impact healthcare. LIfT, with its novel immunotherapy approach, exemplifies the type of company and innovative science that we aim to support and we believe they will be a great fit in our collaborative environment.' As part of the agreement, LIfT will gain access to a cutting-edge innovation space designed to support the unique needs of early-stage biotechs, with the flexibility to expand into larger 'pods' or private lab areas as operations grow. LIfT will also benefit from centralised procurement and operational support, enabling the team to focus on advancing its IMAN platform efficiently and safely. About LIfT BioSciencesLIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by reconstituting immune competence. LIfT's Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable total immune response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See Further informationInvestors:Alex Blyth ablyth@ Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
04-06-2025
- Business
- Business Upturn
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
LIfT BioSciences joins Bayer Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreement with Bayer HealthCare LLC, granting LIfT access to Bayer's state-of-the-art facilities in Cambridge, Massachusetts – one of the world's leading hubs for biotech innovation. This agreement provides LIfT with advanced infrastructure and shared services in a highly collaborative research environment, accelerating the development of its Immuno-Modulatory Alpha Neutrophil (IMAN) platform designed to overcome treatment resistance in solid tumours. ' We see a strong strategic fit with The Bayer Group who have supported using cell therapies to replace dysfunctional cell types in the body in other therapeutic settings, and have developed the world-class facilities and expertise to cost-effectivenely deliver those therapies that we can now look to benefit from. The Bayer offers a unique environment designed to support our kind of biotech innovation, and strengthen our transatlantic presence as we expand as a clinical stage company,' said Alex Blyth, Chief Executive Officer of LIfT Biosciences. Fiona Mack, Head Cambridge at Bayer HealthCare LLC said: 'The was created to provide cutting-edge biotech companies with the space, resources and network they need to accelerate their research and development. portfolio companies have been selected by a panel of experts within Bayer based upon the scientific merit and potential to substantially impact healthcare. LIfT, with its novel immunotherapy approach, exemplifies the type of company and innovative science that we aim to support and we believe they will be a great fit in our collaborative environment.' As part of the agreement, LIfT will gain access to a cutting-edge innovation space designed to support the unique needs of early-stage biotechs, with the flexibility to expand into larger 'pods' or private lab areas as operations grow. LIfT will also benefit from centralised procurement and operational support, enabling the team to focus on advancing its IMAN platform efficiently and safely. About LIfT BioSciences LIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by reconstituting immune competence. LIfT's Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable total immune response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See Further information Investors: Alex Blyth [email protected]
Yahoo
04-06-2025
- Business
- Yahoo
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
LIfT BioSciences joins Bayer Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreement with Bayer HealthCare LLC, granting LIfT access to Bayer's state-of-the-art facilities in Cambridge, Massachusetts – one of the world's leading hubs for biotech innovation. This agreement provides LIfT with advanced infrastructure and shared services in a highly collaborative research environment, accelerating the development of its Immuno-Modulatory Alpha Neutrophil (IMAN) platform designed to overcome treatment resistance in solid tumours. 'We see a strong strategic fit with The Bayer Group who have supported using cell therapies to replace dysfunctional cell types in the body in other therapeutic settings, and have developed the world-class facilities and expertise to cost-effectivenely deliver those therapies that we can now look to benefit from. The Bayer offers a unique environment designed to support our kind of biotech innovation, and strengthen our transatlantic presence as we expand as a clinical stage company,' said Alex Blyth, Chief Executive Officer of LIfT Biosciences. Fiona Mack, Head Cambridge at Bayer HealthCare LLC said: 'The was created to provide cutting-edge biotech companies with the space, resources and network they need to accelerate their research and development. portfolio companies have been selected by a panel of experts within Bayer based upon the scientific merit and potential to substantially impact healthcare. LIfT, with its novel immunotherapy approach, exemplifies the type of company and innovative science that we aim to support and we believe they will be a great fit in our collaborative environment.' As part of the agreement, LIfT will gain access to a cutting-edge innovation space designed to support the unique needs of early-stage biotechs, with the flexibility to expand into larger 'pods' or private lab areas as operations grow. LIfT will also benefit from centralised procurement and operational support, enabling the team to focus on advancing its IMAN platform efficiently and safely. About LIfT BioSciencesLIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by reconstituting immune competence. LIfT's Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable total immune response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See Further informationInvestors:Alex Blyth ablyth@ Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@ 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
22-05-2025
- Business
- Yahoo
LIfT BioSciences presents preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at American Society of Gene & Cell Therapy 28th Annual Meeting, showcasing its versatility in diseases beyond oncology
London, 22 May 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data showing the wider therapeutic potential of its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) was presented at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting held from from 13 – 17 May in New Orleans, USA. The poster highlights how IMANs, while demonstrating strong anti-tumour activity, also harness neutrophil biology to potentially drive immune balance, tissue repair and neuroprotection, underscoring its potential as a scalable, off-the-shelf innunotherapy platform with transformative applications beyond oncology. Key highlights include: N-LIfT platform harnesses pro-homeostatic functions of neutrophils across multiple therapeutic areas, showcasing versatility beyond oncology: The data presented highlights the broad therapeutic potential of LIfT BioSciences' N-LIfT platform, which harnesses the pro-homeostatic functions of neutrophils across multiple disease areas. The poster outlines how IMANs could contribute to clearing senescent cells and promoting tissue repair in ageing; enhancing antimicrobial activity against drug-resistant pathogens; regulating inflammatory responses and gut repair in autoimmune conditions such as Crohn's disease; and supporting neuroregeneration through the secretion of growth factors relevant to CNS disorders. These findings reinforce the versatility of IMANs as a novel cell therapy approach with disease-modifying potential in areas of high unmet need. Robust preclinical efficacy of IMANs across multiple solid tumour models:The data demonstrates the potent anti-tumour activity of IMANs in advanced in vitro models of solid tumours, showing strong tumour infiltration and cytotoxicity in 3D pancreatic cancer microtumour models. Across several patient-derived xenograft organoids, including bladder, colorectal, gastric, pancreatic and non-small cell lung cancer, IMANs drove substantial tumour cell killing. These findings underscore IMANs' broad cytotoxic efficacy and tumour-targeting capability, whether haematopoietic stem cell- or induced pluripotent stem cell-derived, across diverse solid tumour types, highlighting their promise as a versatile and scalable immunotherapy. Poster presentations: Title: IMANs: A Transformative Solution for Overcoming Solid Tumour Immunotherapy Challenges and Rejuvenating Innate Immunity, with Broad Implications for Oncology, Longevity, Autoimmunity, and Neuroinflammation Presenter: Mark A. Exley, Chief Scientific Officer, LIfT BioSciences This posters can be found here. Alex Blyth, Chief Executive Officer of LIfT BioSciences, commented: 'Our poster showcases not only the strong anti-tumour activity of our IMANs across a range of solid tumour models, but also the wider therapeutic potential of our N-LIfT platform beyond oncology. By harnessing the pro-homeostatic functions of neutrophils, IMANs offer a novel approach for longevity, anti-microbial resistance, immunology and neurology. This versatility, supported by a scalable and GMP-compliant manufacturing process, positions IMANs as a first-in-class neutrophil-based immunotherapy with transformative potential. We are proud to be contributing to the future of immunotherapy with a platform that offers real hope for patients across multiple areas of unmet medical need.' About LIfT BioSciencesLIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours. LIfT's Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See Further informationInvestors:Alex Blyth ablyth@ Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
